Arcadia Biosciences (RKDA) 8-K Arcadia Biosciences (RKDA) Announces First Quarter 2023

Exhibit 99.2

 

Arcadia Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share data and per share data)

	Three Months Ended March 31,
		2023			2022
Revenues:
Product	$	1,509		$	3,170
Royalty		—			50
Total revenues		1,509			3,220
Operating expenses (income):
Cost of revenues		825			3,458
Research and development		359			395
Change in fair value of contingent consideration		—			(31	)
Gain on sale of property and equipment		(19	)		(328	)
Selling, general and administrative		4,392			4,349
Total operating expenses		5,557			7,843
Loss from operations		(4,048	)		(4,623	)

# # #

1